SINTES
National Detection System of Drugs and Toxic Substances

The SINTES scheme is intended to document the toxicological composition of illegal substances in circulation in France. The information incorporated in this system comes from two sources:

  • the submission to the OFDT of the results of toxicology tests performed on seizures by law enforcement laboratories (French National Forensic Science Institute, Forensic Sciences Institute of the French gendarmerie and Customs laboratories)
  • investigations conducted by the OFDT on samples of substances obtained directly from users. These collections are governed by a strict regulatory framework and obtained by specifically trained survey workers.

Results

New psychoactive Substances - Ten-year overview of the situation in France
Tendances n° 127, October 2018

New psychoactive substances and the Internet: current situations and issues
Tendances n° 84, January 2013

Recent information on the synthetic drugs circulating in France
Tendances N° 34, February 2004

Ecstasy and other synthetic products in France: situation portrayed by the SINTES facility, 1999-2002
Tendances N° 32, September 2003

 

 

 

 

 

 

 

 

Drugs in Europe


2021 EMCDDA European Drug Report

COVID-19
How is the COVID-19 pandemic affecting drug use, supply and services?
Drug use and harms
What are the health costs of drug use in Europe today?
Drug markets
What do the latest data tell us about drug production and trafficking trends?

These and other questions are explored in the 2021 European Drug Report, our annual overview of the drug situation in Europe.

  Statistical Bulletin 2021

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format..

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.